
News|Videos|September 21, 2023
EVOKE-02: Sacituzumab Govitecan + Pembrolizumab in Non–Small Cell Lung Cancer
Shared insight into data from the EVOKE-02 study of sacituzumab govitecan in combination with pembrolizumab in patients with non–small cell lung cancer stratified by PD-L1 expression.
Episodes in this series






































